|
?:abstract
|
-
COVID-19 disease is caused by a novel type of SARS-CoV-2 virus which was firstly described in Chinese Wuhan in December 2019 It is highly infectious disease manifested with fever, respiratory problems, muscle pains and tiredness Up to now, no efficient medicine has been available, that is why research is focused on development of a vaccine The vaccine research was launched immediately when the pandemic broke out The main goal of vaccination against COVID-19 will be prevention of infection outbreak, prevention of reinfection, long-term protective effect and efficiency of vaccination in case of next potential waves of infection The primary questions are if the effective vaccine against COVID-19 will be developed, how long it will take and who will be the first The first pandemic disease caused by a novel SARS coronavirus emerged almost 20 years ago, the next MERS coronavirus disease 8 years ago and no effective vaccine against these diseases has been available so far Presently, 179 candidate vaccines at minimum are at different stages of their development and 18 vaccines are at the stage of clinical evaluation The surface S glycoprotein SARS-CoV-2 virus is considered the most promising vaccine antigen Other options are the use of the whole virion or subunit S1 carrier Currently, four types of potential vaccines have been developed Whole virion vaccines (attenuated or killed vaccine) vector vaccines (most often using replicating or non-replicating viral vector) protein vaccines (subunit adjuvant vaccine or vaccine based on virus-like particles) and DNA, RNA vaccine The key moment will be confirmation of the novel vaccine efficiency at the phase 3 of a clinical trial Despite pressure and efforts to speed up the development of the vaccine, it is realistic to count on the possible vaccine in the year 2021 the earliest and the question is when it can be available in the Czech Republic
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}